# A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

> **NCT07492615** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 276 (estimated)

## Conditions studied

- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** S-1 & Oxaliplatin

## Key facts

- **NCT ID:** NCT07492615
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2029-02-20
- **Final completion:** 2033-02-20
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07492615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07492615, "A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07492615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*